Literature DB >> 29245008

On the Design of Combination Cancer Therapy.

James H Doroshow1, Richard M Simon2.   

Abstract

Combination therapy programs are the hallmark of the successful treatment of all forms of human malignancies. In this issue of Cell, Palmer and Sorger present data suggesting that cell culture results indicative of synergistic anticancer drug interactions rarely translate clinically and that the results of combination therapies in mouse models or human clinical trials, even if successful, are best explained by the independent activities of the individually administered drugs. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2017        PMID: 29245008      PMCID: PMC7422640          DOI: 10.1016/j.cell.2017.11.035

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  8 in total

Review 1.  Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements.

Authors:  Shivanni Kummar; Helen X Chen; John Wright; Susan Holbeck; Myrtle Davis Millin; Joseph Tomaszewski; James Zweibel; Jerry Collins; James H Doroshow
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 2.  Targeted agents: the rules of combination.

Authors:  Eunice L Kwak; Jeffrey W Clark; Bruce Chabner
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

Review 3.  The use of drugs in combination for the treatment of cancer: rationale and results.

Authors:  V T DeVita; P S Schein
Journal:  N Engl J Med       Date:  1973-05-10       Impact factor: 91.245

Review 4.  Some approaches to the therapeutic exploitation of metabolic sites of vulnerability of neoplastic cells.

Authors:  A C Sartorelli
Journal:  Cancer Res       Date:  1969-12       Impact factor: 12.701

5.  The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia.

Authors:  E Frei; M Karon; R H Levin; E J Freireich; R J Taylor; J Hananian; O Selawry; J F Holland; B Hoogstraten; I J Wolman; E Abir; A Sawitsky; S Lee; S D Mills; E O Burgert; C L Spurr; R B Patterson; F G Ebaugh; G W James; J H Moon
Journal:  Blood       Date:  1965-11       Impact factor: 22.113

Review 6.  Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.

Authors:  Ralph E Parchment; James H Doroshow
Journal:  Semin Oncol       Date:  2016-07-26       Impact factor: 4.929

7.  Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.

Authors:  C G Leichman; T R Fleming; F M Muggia; C M Tangen; B Ardalan; J H Doroshow; F J Meyers; R F Holcombe; G R Weiss; A Mangalik
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

8.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.

Authors:  Adam C Palmer; Peter K Sorger
Journal:  Cell       Date:  2017-12-14       Impact factor: 41.582

  8 in total
  13 in total

1.  Cellular interactions constrain tumor growth.

Authors:  Jeffrey West; Paul K Newton
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-23       Impact factor: 11.205

2.  In situ Injection of pH- and Temperature-Sensitive Nanomaterials Increases Chemo-Photothermal Efficacy by Alleviating the Tumor Immunosuppressive Microenvironment.

Authors:  Jianhua Liu; Liantao Guo; Yan Rao; Weijie Zheng; Dongcheng Gao; Jing Zhang; Lan Luo; Xinwen Kuang; Saraswati Sukumar; Yi Tu; Chuang Chen; Shengrong Sun
Journal:  Int J Nanomedicine       Date:  2022-06-16

3.  Decreased DNA Damage and Improved p53 Specificity of RITA Analogs.

Authors:  Yue Zhan; Xiaolei Zhou; Sylvain Peuget; Madhurendra Singh; Brian D Peyser; Zhimin Fan; Galina Selivanova
Journal:  Mol Cancer Ther       Date:  2022-10-07       Impact factor: 6.009

Review 4.  Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.

Authors:  Kasturee Chakraborty; Archana Tripathi; Sukumar Mishra; Argha Mario Mallick; Rituparna Sinha Roy
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

Review 5.  Machine learning approaches for drug combination therapies.

Authors:  Betül Güvenç Paltun; Samuel Kaski; Hiroshi Mamitsuka
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

6.  Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells.

Authors:  Arem Qayum; Asmita Magotra; Syed Mohmad Shah; Utpal Nandi; P R Sharma; Bhahwal Ali Shah; Shashank Kumar Singh
Journal:  Heliyon       Date:  2022-03-16

7.  Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors.

Authors:  Adam C Palmer; Benjamin Izar; Haeun Hwangbo; Peter K Sorger
Journal:  Clin Cancer Res       Date:  2022-01-15       Impact factor: 13.801

8.  A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas.

Authors:  Robert Meehan; Shivaani Kummar; Khanh Do; Geraldine O'Sullivan Coyne; Lamin Juwara; Jennifer Zlott; Larry Rubinstein; James H Doroshow; Alice P Chen
Journal:  Oncologist       Date:  2018-05-31

9.  Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer.

Authors:  Alina Malyutina; Muntasir Mamun Majumder; Wenyu Wang; Alberto Pessia; Caroline A Heckman; Jing Tang
Journal:  PLoS Comput Biol       Date:  2019-05-20       Impact factor: 4.475

10.  Picropodophyllotoxin, an Epimer of Podophyllotoxin, Causes Apoptosis of Human Esophageal Squamous Cell Carcinoma Cells Through ROS-Mediated JNK/P38 MAPK Pathways.

Authors:  Ah-Won Kwak; Goo Yoon; Mee-Hyun Lee; Seung-Sik Cho; Jung-Hyun Shim; Jung-Il Chae
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.